- Company
- New drug 'Truqap' for HER2- breast cancer Rx available
- by Son, Hyung Min Jan 8, 2025 05:53am
- 'Truqap,' an oral anticancer drug that targets AKT gene mutation, is now available for prescription at general hospitals. According to industry sources, AstraZeneca Korea's Truqap (capivasertib), a treatment for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, has passed t
- Company
- Twice yearly HIV drug 'lenacapavir' receives ODD
- by Eo, Yun-Ho Jan 7, 2025 06:05am
- Twice yearly injectable 'lenacapavir' for HIV prevention has been designated as an orphan drug in South Korea. The Ministry of Food and Drug Safety (MFDS) recently announced this through the new year's first orphan drug designation notification. The drug is indicated 'In combination with other antiretroviral therapy, for treatment of p
- Company
- AstraZeneca Korea recertified Innovative Pharma Company
- by Whang, byung-woo Jan 7, 2025 06:05am
- AstraZeneca Korea announced today that it has successfully extended its certification as a 2024 Innovative Pharmaceutical Company by the Ministry of Health and Welfare. This marks the third consecutive recertification since the company was first certified in 2018, and recognizes the company's steady R&D investments and achievements made t
- Company
- 1st RSV preventive inj 'Beyfortus' can be prescribed
- by Eo, Yun-Ho Jan 6, 2025 05:56am
- The first injectable antibody drug approved in South Korea to prevent respiratory syncytial virus (RSV), 'Beyfortus,' is now available for prescription at general hospitals. According to industry sources, Sanofi Korea's Beyfortus (nirsevimab) has passed the drug committees (DC) of medical centers, including Seoul National University Hospi
- Company
- Balversa may be prescribed at general hospitals in Korea
- by Eo, Yun-Ho Jan 6, 2025 05:56am
- The new bladder cancer drug Balversa may now be prescribed in Korea’s Big 5 tertiary hospitals in Korea. According to industry sources, Janssen Korea's FGFR-inhibiting urothelial carcinoma (bladder cancer) drug Balversa (erdafitinib) recently passed the drug committees (DCs) of tertiary hospitals including Samsung Medical Center, Seoul Na
- Company
- Lily's 'Jaypirca' launches in KOR
- by Whang, byung-woo Jan 3, 2025 06:28am
- Lily Korea announced on January 2 that Jaypirca (ingredient name: pirtobrutinib), a treatment for mantle cell lymphoma (MCL), was launched in South Korea on December 26. To date, Jaypirca is the first reversible Bruton's tyrosine kinase (BTK) inhibitor of any kind. Jaypirca was approved by the Ministry of Food and Drug Saftey (MFDS) i
- Company
- Will Fabhalta settle as a PNH treatment option in Korea?
- by Eo, Yun-Ho Jan 3, 2025 06:27am
- Whether another PNH treatment option will be born is gaining attention in Korea. According to industry sources, Novartis Korea has submitted a reimbursement application for its oral paroxysmal nocturnal hemoglobinuria (PNH) treatment Fabhalta (iptacopan). PNH is a rare disease with an estimated incidence of 1.5 per million people world
- Company
- Yuhan’s anticancer drug Leclaza secures European approval
- by Cha, Jihyun Jan 2, 2025 06:10am
- Yuhan Corp’s new anti-cancer drug Leclaza (Lazertinib) has crossed the European threshold. The European Commission (EC) approved the drug a month after receiving a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). As a result, the company will receive a USD 30 million European
- Company
- K-Bio to showcase CDMO·new drugs at the JP Morgan
- by Son, Hyung Min Jan 2, 2025 06:10am
- The Korean pharmaceutical and biotech industry is set to participate in the new year's first global event, the JP Morgan Healthcare Conference. Attention has been drawn to what the Korean pharmaceutical and biotech industry will accomplish during the event, which will include discussions of blockbuster technology transfers and partnering a
- Company
- Yuhan Corp will distribute Canesten·Bepanthen
- by Nho, Byung Chul Dec 30, 2024 05:57am
- Yuhan Corp has been selected as the new distribution partner for Bayer’s Canesten and Bepanthen. According to industry sources, Bayer Korea recently terminated its 10-year co-promotion agreement with Ildong Pharmaceutical and signed a new distribution agreement with Yuhan Corp. Under the new agreement, Yuhan Corp will take over the
